Single User
£3750
PDF
40 pages

Age-related Macular Degeneration (AMD) Disease in 7 Major Markets 2016-2026


Age-related macular degeneration (AMD or ARMD) or Age-related Maculopathy (ARM) is a condition that involves the degeneration and damage to the central area of the retina – the macula. It is currently a common cause of visual impairment in Western Europe. AMD is typically painless, and the loss of central vision usually occurs in both eyes but may progress at different speeds.

This report provides the current prevalent population for AMD across 7 Major Markets (USA, France, Germany, Italy, Spain, UK and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AMD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AMD include:

  • Serous retinal detachment
  • Haemorrhage
  • Charles Bonnet Syndrome
  • Depression
  • Reduced quality of life
  • Hypertension
  • Hypercholesterolaemia (abdominal obesity is a specific risk factor for males)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global AMD’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of AMD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AMD’s prevalent population.
  • Identify sub-populations within AMD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AMD patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Age-Related Macular Degeneration
  • Features of AMD Patients
    • Severity and Type of AMD
    • Early Type AMD
    • Late Type AMD
    • AMD Associated Conditions
    • Exudative AMD Associated Conditions
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • AMD stages
  • Prevalence of AMD, total (000s)
  • Prevalence of AMD, males (000s)
  • Prevalence of AMD, females (000s)
  • Severity of AMD in patients, total (000s)
  • Early AMD by diameter (µm) of drusen present, total (000s)
  • Late AMD patients by type, total (000s)
  • Pigmentation abnormality in Early AMD patients, total (000s)
  • Type of CNV in Exudative AMD patients, total (000s)
  • Classic CNV location in Exudative AMD patients, total (000s)
  • Occult CNV location in Exudative AMD patients, total (000s)
  • Pattern of increased FAF at junctional zone in GA AMD patients, total (000s)
  • Prevalence of diabetes in AMD, total (000s)
  • Prevalence of hypertension in AMD, total (000s)
  • Prevalence of retinal detachment in Exudative AMD patients, total (000s)
  • Prevalence of subretinal haemorrhage in Exudative AMD patients, total (000s)
  • Prevalence of subretinal scarring in Exudative AMD patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of AMD by 5-yr age cohort, males (000s)
  • USA Prevalence of AMD by 5-yr age cohort, females (000s)
  • France Prevalence of AMD by 5-yr age cohort, males (000s)
  • France Prevalence of AMD by 5-yr age cohort, females (000s)
  • Germany Prevalence of AMD by 5-yr age cohort, males (000s)
  • Germany Prevalence of AMD by 5-yr age cohort, females (000s)
  • Italy Prevalence of AMD by 5-yr age cohort, males (000s)
  • Italy Prevalence of AMD by 5-yr age cohort, females (000s)
  • Spain Prevalence of AMD by 5-yr age cohort, males (000s)
  • Spain Prevalence of AMD by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of AMD by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of AMD by 5-yr age cohort, females (000s)
  • Japan Prevalence of AMD by 5-yr age cohort, males (000s)
  • Japan Prevalence of AMD by 5-yr age cohort, females (000s)
France, Germany, Italy, Japan, Spain, United Kingdom, United States of America